Watch: New Cancer Drugs from Artificial Life

In 2014 artificial life was made for the first time.

Two new nucleotides were added—X and Y—to the standard four: A, G, T, C

These new nucleotides allow for the addition of unnatural amino acids to create entirely new kinds of proteins.

Now biotech company Synthorx has announced that they have developed a new cancer drug using these artificial bacteria.

Interleukin-2 has been studied for decades as an immune system-stimulating cancer therapy, but it unfortunately comes with some serious side effects and is often unpredictable.

By adding an extra unnatural amino acid to Interleukin, Synthorx created a “Synthorin” that prolongs the protein’s activity while eliminating its immune-suppressing effects.

So, it turns out that creating artificial life is more than a cool laboratory trick—it may turn out to be a great new way to create new drugs as well.

http://www.sandiegouniontribune.com/business/biotech/sd-me-synthorx-cancer-20180430-story.html

Follow us on social media for the latest updates in B2B!

Image

Latest

promoted
How to Succeed After Getting Promoted: Seeking Feedback, Acting with Intention, and Leading with Perspective
April 16, 2026

Stepping into a leadership role today isn’t just a step up—it’s a shift into constant visibility, where expectations arrive immediately and the margin for error narrows. As organizations flatten structures and demand faster decisions, newly promoted leaders are expected to deliver impact from the outset, often without the space to fully adjust. According to…

Read More
AI in business
A Practical Conversation About AI in Business: From Hype to Real-World Impact
April 15, 2026

Artificial intelligence has moved from buzzword to boardroom priority at a staggering pace. Yet despite widespread adoption, many organizations are still struggling to turn experimentation into measurable business value—some estimates suggest the majority of enterprise AI initiatives fail to scale successfully. As AI becomes “table stakes” across industries, the real challenge is no longer…

Read More
weekly drive-in
Metropolis: Weekly Drive-in
April 15, 2026

Metropolis “Weekly Drive In” reflects a new era of storytelling where AI meets real-world execution, turning everyday field performance into momentum. Centered on genuine conversions and local wins, the series highlights how the company is scaling not just through technology, but through visibility and shared recognition. In an emerging recognition economy, these updates act…

Read More
Drive In, Drive Out: The Rhythm of Metropolis
April 15, 2026

Behind the seemingly mundane choreography of a drive-in lies a broader story about how modern cities script behavior, turning even the simplest actions into rehearsed routines. What looks like repetition is really a quiet testament to systems designed for flow and control, where efficiency often outweighs individuality. In places like Metropolis, the rhythm of…

Read More